1.21  0.14 (13.08%)		01-23 16:00
Open: 1.085 High: 1.23 Volume: 2,465,976		Pre. Close: 1.07 Low: 1.07 Market Cap: 123(M)

Short term
Mid term
Targets	6-month :	1.63	1-year :	1.9
Resists	First :	1.4	Second :	1.62
Pivot price	1.17
Supports	First :	1.03	Second :	0.86
MAs	MA(5) :	1.16	MA(20) :	1.15
	MA(100) :	1.12	MA(250) :	1.19
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	16	D(3) :	36.6
RSI	RSI(14): 55.9
52-week	High :	1.79	Low :	0.86

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ LUCD ] has closed below upper band by 34.3%. Bollinger Bands are 17.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	1.23 - 1.24	1.24 - 1.24
Low:	1.05 - 1.06	1.06 - 1.07
Close:	1.2 - 1.21	1.21 - 1.22

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

Fri, 23 Jan 2026
Individual investors among Lucid Diagnostics Inc.'s (NASDAQ:LUCD) largest stockholders and were hit after last week's 14% price drop - simplywall.st

Wed, 21 Jan 2026
Why Is PAVmed Stock Skyrocketing Wednesday? - Benzinga

Wed, 21 Jan 2026
Why Are PAVmed (PAVM) & Lucid Diagnostics (LUCD) Stocks Up Today? - TipRanks

Wed, 21 Jan 2026
PAVmed-unit Lucid Diagnostics spikes on VA contract (LUCD) - Seeking Alpha

Wed, 21 Jan 2026
VA taps Lucid's EsoGuard cancer test, opening access for 9M veterans - Stock Titan

Wed, 21 Jan 2026
Lucid Diagnostics Awarded U.S. Department of Veterans Affairs Contract for EsoGuard® - PR Newswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Devices
Shares Out	131 (M)
Shares Float	88 (M)
Held by Insiders	35.2 (%)
Held by Institutions	28.5 (%)
Shares Short	4,750 (K)
Shares Short P.Month	3,950 (K)

EPS	-0.77
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-0.24
Profit Margin	0 %
Operating Margin	-971.1 %
Return on Assets (ttm)	-79.2 %
Return on Equity (ttm)	-331.3 %
Qtrly Rev. Growth	3.2 %
Gross Profit (p.s.)	-0.02
Sales Per Share	0.03
EBITDA (p.s.)	-0.36
Qtrly Earnings Growth	0 %
Operating Cash Flow	-44 (M)
Levered Free Cash Flow	-26 (M)

PE Ratio	-1.58
PEG Ratio	0
Price to Book value	-5.27
Price to Sales	36.05
Price to Cash Flow	-3.63

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.